Hey, all, welcome back to the Real Life Pharmacology podcast. I'm your host, pharmacist, Derek Christensen.

Thank you so much for listening today.

So always go check out Real Life Pharmacology.com when you subscribe there via email.

We'll shoot you out a top 200 study guides, 31 page PDF, lots of info there.

I've pulled in lots of clinical practice pearls, as well as things that often show up on board exams

or pharmacology exams throughout your career.

So a lot of good experience, valuable information within that document.

So go snag that for free at real-life pharmacology.com.

All right, the drug of the day today is glomepiride.

Brand name of this medication is amaryl.

And this drug is a sulfonyerea. So if you don't remember, we have covered, I believe,

two sulfonyrias already maybe. Glypazide probably being the most prominent one that I've seen

used in practice. But I definitely come across glimaparide a fair amount as well and just did the other day.

Mechanistically, a sulfonyerea stimulates the release of insulin from beta cells.

And those beta cells, again, are in the pancreas.

So that's important to remember from an adverse effect standpoint.

So if you think about that, we're stimulating the release of insulin.

So essentially it's like we're giving extra insulin.

So you could anticipate that the adverse effect profile is basically going to mimic or be similar in many ways to giving

insulin. So thinking about that, adverse drug reactions, low blood sugars, weight gain,

those are going to be the most prominent adverse effects there. I'll get into those

a little bit more. Use is obviously diabetes. It is only indicated for type 2 diabetes. Oral

...